AI-designed vaccines could transform pandemic preparedness by moving from reactive to proactive defense. A University of Cambridge-led trial of the pEVAC-PS vaccine demonstrated that an AI-generated “super-antigen” is safe in humans. While immune responses remain modest, the technology aims to target entire families of viruses before they spill over into the population.
How does AI-driven vaccine design work?
For most of modern vaccine history, scientists have been forced to play catch-up. When a new virus emerges, researchers race to sequence its genome and build a shot while people are already getting sick. This reactive cycle often leaves the public vulnerable to rapidly mutating strains.
The University of Cambridge team is attempting to flip this script. Instead of waiting for a specific virus to appear, they used machine-learning tools to scan genetic data from known sarbecoviruses—the group containing SARS-CoV-2 and related bat viruses. The AI searched for shared structures in the receptor binding domain, which is the part of the spike protein the virus uses to enter human cells.
The result is a “super-antigen.” This is a synthetic target designed to train the immune system to recognize features that are consistent across many different viruses. By focusing on these conserved regions, the vaccine aims to remain effective even as individual strains mutate.
“We’ve converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains,” said Professor Jonathan Heeney of the University of Cambridge, the scientific lead of the research.
Most current vaccines, like those for the seasonal flu or updated COVID-19 boosters, must be frequently reformulated because they target specific, circulating versions of a virus. A “super-antigen” tries to bypass this constant need for updates.
What did the first-in-human trial reveal?
The experimental shot, known as pEVAC-PS, underwent a small first-in-human trial involving 39 healthy adults between the ages of 18 and 50. According to results published in the Journal of Infection, the vaccine was deemed safe and well tolerated.
Participants received two doses, 28 days apart, at four different levels: 0.2 milligrams, 0.4 milligrams, 0.8 milligrams, and 1.2 milligrams. The researchers reported no serious adverse reactions, no suspected serious adverse reactions, and no serious adverse events. Most side effects were mild or moderate, including:
- Fatigue
- Pain at the injection site
- Redness
- Warmth
While the safety profile is encouraging, the efficacy data is more nuanced. The study found modest antibody responses, and researchers did not see a strong, predictable dose-response pattern. While there was some evidence that participants recognized conserved sarbecovirus regions, the study authors noted that the results “do not yet substantiate broad or robust neutralizing activity.”
Could needle-free DNA vaccines solve global logistics?
Beyond the AI design, the delivery method of pEVAC-PS could change how vaccines are distributed globally. The vaccine is a DNA vaccine, which uses non-replicating plasmid DNA. Because this technology is more stable than many other vaccine types, it could potentially reduce the need for the expensive, ultra-cold storage chains that complicate mass vaccination in many parts of the world.
Furthermore, the trial used a PharmaJet Tropis device to deliver the vaccine into the skin without a needle. This approach could simplify large-scale campaigns and reduce medical waste. It might also help overcome “needle phobia,” a common barrier to vaccine uptake.
When evaluating new vaccine technologies, look for “non-replicating” designations. In the case of pEVAC-PS, researchers explained that the DNA lacks the ability to insert itself into human DNA, making the risk of genomic integration extremely low.
What is the future of universal vaccines?
The work at Cambridge is part of a much larger global effort to develop “universal vaccines”—shots that protect against entire families of viruses rather than single strains. This includes long-standing research into universal flu and Ebola vaccines.
Professor Saul Faust of the University of Southampton, the trial’s chief investigator, emphasized the economic and human stakes. “If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided and the economy preserved,” he stated.
The next step for pEVAC-PS is a larger Phase 2 trial. This upcoming study will involve approximately 200 people to more thoroughly examine immune responses in a broader group.
Frequently Asked Questions
Is the pEVAC-PS vaccine currently available to the public?
No. It is currently in the experimental stage and has only been tested in a small clinical trial of 39 adults.
Can this vaccine change my DNA?
No. Researchers stated that because the vaccine uses non-replicating plasmid DNA, it lacks the ability to insert itself into human DNA.
Does this vaccine protect against all COVID-19 variants?
The goal is to protect against a wide family of viruses (sarbecoviruses), but current trial results show only “modest” immune responses and do not yet prove broad or robust protection.
What do you think about the use of AI in medicine? Could proactive vaccines be the key to preventing the next lockdown? Let us know your thoughts in the comments below, and subscribe to our newsletter for the latest updates on medical breakthroughs.
